Home > Blog > Planning the way forward for a new tumor evaluation modality

RECIST (Response Evaluation Criteria in Solid Tumors) guidelines were introduced over twenty years ago to provide a standard for evaluating tumor response, with the goal of maintaining consistency at sites and across sites as well as limiting any site bias. 

With the introduction of intratumoral (IT) immunotherapies, IT immunotherapy RECIST (itRECIST) is proposed to capture data and assess local and systemic responses in a standardized fashion for clinical trials involving these therapies.

 

CS thumbnail_itRECIST tumor modalityOvercoming Methodology Hurdles
Veristat helped a sponsor write the protocol for a novel treatment that injects engineered exosomes into solid tumors. The application of a set of nuanced response criteria required information collected from injected and non-injected lesions to determine a tumor’s response to the treatment.

 

itRECIST criteria were used in this scenario to measure changes in tumor size; but as this is a new method for tracking a novel treatment, protocols had to be developed.

 

Access the Full-Length Case Study

Read the case study to learn more about how our team defined the appropriate methodology for collection and data analysis in this largely untested area of clinical development.

 

DOWNLOAD CASE STUDY

 


 

Explore Related Services:

 

 

1 min read

Advanced Therapies Congress

Meet Veristat at the Advanced Therapies Congress 2025

Veristat is excited to participate in the Advanced Therapies...

1 min read

DIA Europe

Meet Veristat at DIA Europe 2025

Discover what makes Veristat a distinguished name in the life sciences industry....